{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:12:08Z","timestamp":1648649528263},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"DOI":"10.1093\/ajhp\/59.3.254","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T22:07:43Z","timestamp":1550873263000},"page":"254-260","source":"Crossref","is-referenced-by-count":4,"title":["Implications of prion-induced diseases for animal-derived pharmaceutical products"],"prefix":"10.1093","volume":"59","author":[{"given":"Brian L.","family":"Erstad","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, 1703 E. Mabel Street, Tucson, AZ 85721-0207"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/59\/3\/254\/28436832\/ajhp0254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T17:12:37Z","timestamp":1555348357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/59\/3\/254\/5157936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/59.3.254","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,2,1]]},"published":{"date-parts":[[2002,2,1]]}}}